Clinical Evaluation of CYFRA 21-1 in Malignant Pleural Fluids

Satoh, Hiroaki; Sumi, Masahiro; Yagyu, Hisanaga; Ishikawa, Hiroichi; Suyama, Takuya; Naitoh, Takeshi; Saitoh, Tamotsu; Hasegawa, Shizuo

doi:10.1159/000227459

Cited by 25 publications

(16 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, Romero et al (1996) observed a sensitivity of only 38% for CYFRA, in a small series of 41 malignant effusions. Thus, our results agree with those of Satoh et al (1995) and Toumbis et al (1996), and we confirm that CYFRA is one of the most efficient tumour markers available for the diagnosis of malignant effusions.…”

Section: Discussionsupporting

confidence: 93%

“…Consequently, when we only considered the group of carcinomas and mesotheliomas, the sensitivity of CEA and CYFRA appeared to be significantly higher (64.7% and 58.8% respectively), reaching the levels of sensitivity previously described for various tumour markers, such as CEA, CA 72-4 or CA 15-3 (Ferroni et al, 1990;Rapellino et al, 1990;Villena et al, 1996). Satoh et al (1995) and Toumbis et al (1996) described similar results for CYFRA, but Satoh reported a higher sensitivity for CYFRA than for CEA. On the other hand, Romero et al (1996) observed a sensitivity of only 38% for CYFRA, in a small series of 41 malignant effusions.…”

Section: Discussionmentioning

confidence: 62%

“…Moreover, CYFRA is presented as the most sensitive serum tumour marker in squamous cell lung carcinomas (Pujol et al, 1993;Stieber et al, 1993; Van der Gaast et al, 1994;Plebani et al, 1995) and is of potential interest in squamous cell carcinomas of the uterine cervix (Ferdeghini et al, 1994) or head and neck (Doweck et al, 1995). In pleural effusions, Toumbis et al (1996) and Satoh et al (1995) observed a high sensitivity for CYFRA in squamous cell lung carcinomas. Despite the small size of the group of squamous cell carcinomas, our results lead to the same conclusion.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions

Salama

Miédougé²,

Rouzaud³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary CYFRA 21-1 assay, measuring cytokeratin 19 fragments, was compared with carcinoembryonic antigen (CEA) assay, as an addition to cytological analysis for the diagnosis of malignant effusions. Both markers were determined with commercial enzyme immunoassays in pleural fluid from 196 patients. Cytological analysis and/or pleural biopsy confirmed the malignant origin of the effusion in 99 patients (76 carcinomas, nine pleural mesotheliomas and 14 non-epithelial malignancies). Effusions were confirmed as benign in 97 patients (33 cardiac failures, 39 infectious diseases -including 12 tuberculosis -and 25 miscellaneous effusions). Both markers were significantly higher in malignant than in benign effusions. All the patients with non-epithelial malignancies presented CYFRA and CEA values lower than the 95% diagnostic specificity thresholds (100 and 6 ng ml-' respectively). The diagnostic sensitivity in the group of carcinomas and mesotheliomas was similar for CYFRA (58.8%) and CEA (64.7%). However, CEA had a significantly higher sensitivity in carcinomas (72.4% vs 55.3%), while CYFRA had a clearly higher sensitivity in mesotheliomas (89.9% vs 0%). Interestingly, 12 out of the 16 malignant effusions with a negative cytology were CEA and/or CYFRA positive. Regarding their high diagnostic sensitivity and their complementarity, CEA and CYFRA appear to be very useful for the diagnosis of malignant pleural effusions when cytology is negative.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions

Salama

Miédougé²,

Rouzaud³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Furthermore, compared to CEA and CA 72-4, CA 15-3 showed an atypical pattern in mesotheliomas, with a sensitivity of 45.5%, in agreement with the results of Villena et al (1996). The data published for pleural CYFRA are more controversial, notably concerning the thresholds and the overall sensitivity which is described as either higher (Satoh et al, 1995) or lower than the sensitivity of CEA (Romero et al, 1996). Confirming our prior study (Salama et al, 1998), we observed similar sensitivities for pleural CEA and pleural CYFRA but above all, a high sensitivity for pleural CYFRA in mesotheliomas.…”

Section: Discussionsupporting

confidence: 78%

Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions

et al. 1999

View full text Add to dashboard Cite

Summary Carcinoembryonic antigen (CEA), carbohydrate antigens , cytokeratin 19 fragments (CYFRA 21-1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a specificity of 99%, determined in a series of 121 benign effusions, the best individual diagnostic sensitivities in the whole series of 215 malignant effusions or in the subgroup of adenocarcinomas were observed with CEA, CA 15-3 and CA 72-4. As expected, a high sensitivity was obtained with SCC in squamous cell carcinomas and with NSE in small-cell lung carcinomas. CYFRA and/or CA 15-3 were frequently increased in mesotheliomas. Discriminant analysis showed that the optimal combination for diagnosis of nonlymphomatous malignant effusions was CEA + CA 15-3 + CYFRA + NSE: sensitivity of 94.4% with an overall specificity of 95%. In malignant effusions with a negative cytology, 83.9% were diagnosed using this association. The association CYFRA + NSE + SCC was able to discriminate adenocarcinomas from small-cell lung cancers. Regarding their sensitivity and their complementarity, CEA, CA 15-3, CYFRA 21-1, NSE and SCC appear to be very useful to improve the diagnosis of malignant pleural effusions.

show abstract

“…An accurate diagnosis can be madeif the cytologic, histologic, or bacteriologic results are positive. Various biomarkers in the pleural effusion have been investigated to distinguish malignant effusions from benign (1)(2)(3)(4)(5). However, their usefulness in the diagnosis of pleural effusions has not been fully established.…”

Section: Introductionmentioning

confidence: 99%

Elevated Sialyl Lewis X-i Antigen Levels in Pleural Effusions in Patients with Carcinomatous Pleuritis.

et al. 1997

Self Cite

View full text Add to dashboard Cite

The levels ofsialyl Lewis X-i antigen (SLX), which is one of the cancer-associated carbohydrate antigens, were evaluated in 83 malignant and 46 benign pleural effusions. SLXlevels in pleural effusion due to lung adenocarcinoma were significantly higher than those due to benign diseases (p<0.0001), lung cancer other than adenocarcinoma (p=0.0052), and adenocarcinoma originating from other organs (p=0.0492). According to receiver operating characteristic (ROC) curve analysis, the optimal cut-off level in the discrimination between malignant and benign pleural effusions was 92 U/ml, which gave a sensitivity of57.1 %and a specificity of77.8 %. The cut-off level of pleural effusion in patients with carcinomatous pleuritis might be higher than that of serum (38 U/ml). (Internal Medicine 36: 685-689, 1997)

show abstract

Clinical Evaluation of CYFRA 21-1 in Malignant Pleural Fluids

Cited by 25 publications

References 7 publications

Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions

Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions

Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions

Elevated Sialyl Lewis X-i Antigen Levels in Pleural Effusions in Patients with Carcinomatous Pleuritis.

Contact Info

Product

Resources

About